FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation.
Saved in:
| Title: | FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation. |
|---|---|
| Authors: | Zhou Q; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China., Li J; Department of Medical Oncology, Beijing Chest Hospital, Capital Medical University, Beijing, China., Cang SD; Department of Medical Oncology, Henan Provincial People's Hospital, Zhengzhou, China., Lin JX; Pulmonary Medicine, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China., Tu HY; Pulmonary Medicine, Guangdong Provincial People's Hospital, Southern Medical University, Guangzhou, China., Du Y; Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China., Qin JW; Respiratory Medicine, Tianjin Chest Hospital, Tianjin, China., Liang XH; Department of Oncology, Huashan Hospital, Fudan University, Shanghai, China., Yu Y; Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China., Lan HT; Department of Medical Oncology, Sichuan Provincial People's Hospital, Sichuan Academy of Medical Sciences, School of Medicine UESTC, Chengdu, China., Shi HQ; Department of Medical Oncology, First Affiliated Hospital of Gannan Medical University, Ganzhou, China., Hua D; Department of Medical Oncology, Wuxi People's Hospital, Wuxi, China., Liu SM; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China; Chinese Thoracic Oncology Group (CTONG), Guangzhou, China., Wu YL; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China. Electronic address: syylwu@live.cn. |
| Source: | Clinical lung cancer [Clin Lung Cancer] 2025 Mar; Vol. 26 (2), pp. 152-157.e1. Date of Electronic Publication: 2024 Sep 20. |
| Publication Type: | Clinical Trial Protocol; Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 100893225 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0690 (Electronic) Linking ISSN: 15257304 NLM ISO Abbreviation: Clin Lung Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
